Osaic Holdings’s TScan Therapeutics TCRX Stock Holding History

Osaic Holdings’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.85K	Sell	9,756 -2,489	-20%	-$2.66K	﹤0.01%	6299
2025 Q4	$12.2K	Hold	12,245	–	–	﹤0.01%	6211
2025 Q3	$21.9K	Hold	12,245	–	–	﹤0.01%	5869
2025 Q2	$17.8K	Sell	12,245 -2,489	-17%	-$3.6K	﹤0.01%	5802
2025 Q1	$20.3K	Buy	14,734 +2,489	+20%	+$5.38K	﹤0.01%	5359
2024 Q4	$37.2K	Hold	12,245	–	–	﹤0.01%	4912
2024 Q3	$61K	Hold	12,245	–	–	﹤0.01%	4600
2024 Q2	$71.6K	Buy	+12,245	New	+$96.4K	﹤0.01%	4394
2023 Q2	–	Sell	-1	Closed	-$2	–	7577
2023 Q1	$2	Buy	+1	New	+$2	﹤0.01%	7481

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Osaic Holdings's TCRX Position: Q1 2026 in Review

Osaic Holdings reduced its TScan Therapeutics (TCRX) stake by 20% in Q1 2026, selling an estimated $2.66K and leaving 9,756 shares worth $9.85K. The position accounts for ﹤0.01% of the portfolio, ranked #6299.

Osaic Holdings first reported a position in TCRX in Q1 2023 and has held it in 9 quarters since. The position peaked at $71.6K in Q2 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

Osaic Holdings held 9,756 shares of TScan Therapeutics worth $9.85K as of Q1 2026.
Osaic Holdings sold 2,489 TScan Therapeutics shares in Q1 2026, an estimated $2.66K.
TScan Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #6299 holding.
Osaic Holdings first reported a position in TScan Therapeutics in Q1 2023 and has held it in 9 quarters since.
Osaic Holdings's TScan Therapeutics position peaked at $71.6K in Q2 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.